Top Markets
#1 Gravity Gravity +68.84%
#2 Galxe Galxe +41.90%
#3 Aria.AI Aria.AI +26.39%
#4 Audiera Audiera +23.18%
#5 Velas Velas +23.15%
#6 Codatta Codatta +20.32%
#7 Pepe Pepe +18.90%
#8 Derive Derive +18.72%
#9 MemeCore MemeCore +15.75%
#10 Memetern Memetern +15.17%
Coin of the day
Gravity Gravity
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Peringkat dalam Saham #157
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Harga Saham
$469.34
Kapitalisasi Pasar
$119.21B
Perubahan (1 hari)
-1.84%
Perubahan (1 tahun)
-7.87%
Negara
US
Perdagangan Vertex Pharmaceuticals Incorporated (VRTX)

Kategori

Healthcare
Kapitalisasi Pasar
Pendapatan
lebih banyak
Keuntungan
Riwayat Harga
Rasio P/E
Rasio P/S
Rasio P/B
Margin Operasi
EPS
Pemecahan Saham
Dividen
Hasil Dividen
Saham Beredar
Rasio P/E untuk Vertex Pharmaceuticals Incorporated (VRTX)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Vertex Pharmaceuticals Incorporated, rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk Vertex Pharmaceuticals Incorporated dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.07 -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 38.30 -
NL
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.